Cat. No. | Product name | CAS No. |
DC10131 |
BMS-986205(Linrodostat)
Featured
BMS-986205 is an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic activity, alone and in combination with nivolumab in advanced cancers in a phase 1/2a trial |
1923833-60-6 |
DC8389 |
Epacadostat (INCB024360)
Featured
Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with IC50 of 10 nM. Phase 2. |
1204669-58-8 |
DC10098 |
IDO-IN-1
Featured
IDO-IN-1 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50 of 59 nM, shows activity in Hela cell (IC50=12 nM). |
914638-30-5 |
DC10421 |
IDO-IN-2
Featured
IDO-IN-2 is an IDO inhibitor extracted from patent WO/2015031295 A1, compound example 1, has IC50 values of 0.068 μM in HeLa cell and 0.16 μM in HEK293 cell. |
1668565-74-9 |
DC7015 |
INCB024360 analogue(IDO-IN-1)
Featured
INCB024360 is a potent IDO1 inhibitor(IC50=10 nM) with desirable pharmaceutical properties, which is poised to start clinical trials in cancer patients. |
914471-09-3 |
DC8021 |
Indoximod (NLG-8189)
Featured
NLG-8189 is an inhibitor of IDO and INDOL1 (IDO2) |
110117-83-4 |
DC10022 |
PF06840003
Featured
PF-06840003 is an orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1),with potential immunomodulating and antineoplastic activities. |
198474-05-4 |
DC11159 |
Roxyl-WL
Roxyl-WL is a highly potent and selective inhibitor of IDO1 with IC50 of 1 nM. |
667887-37-8 |
DC28283 |
(Rac)-IDO1-IN-5
(Rac)-IDO1-IN-5 (Example 1) is a racemate of IDO1-IN-5. IDO1-IN-5 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1. |
2166616-74-4 |
DC28284 |
(S)-IDO1-IN-5
(S)-IDO1-IN-5 (Example 1B) is an active S-isomer of IDO1-IN-5. (S)-IDO1-IN-5 binds to IDOL with an IC50 value less than 1.5 µΜ. IDO1-IN-5 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1. |
2166616-76-6 |
DC28673 |
IDO1-IN-2
IDO1-IN-2 (compound 16) is a potent and selective IDO1 inhibitor with IC50s of 81 nM, 59 nM (mouse) and 28 nM (rat), respectively. IDO1-IN-2 has anti-cancer activity. |
2346614-58-0 |
DC40744 |
(Rac)-Indoximod
(Rac)-Indoximod (1-Methyl-DL-tryptophan) is an indoleamine 2,3-dioxygenase (IDO) inhibitor. Co-treatment with IFN-γ and (Rac)-Indoximod markedly reduces the activity of human cardiac myofibroblasts (hCMs) expressing α-SMA and induces apoptosis through up-regulating the IRF-1, Fas, and FasL genes. |
26988-72-7 |
DC42337 |
IDO-IN-6
IDO-IN-6 (NLG-1486) is an indoleamine 2,3-dioxygenase (IDO) extracted from patent WO WO2012142237A1, Compound 1486, has an IC50 of <1 μM. |
1402837-76-6 |
DC42338 |
IDO-IN-8
IDO-IN-8 (NLG-1487) is an indoleamine 2,3-dioxygenase (IDO) extracted from patent WO WO2012142237A1, compound 1487, has an IC50 of 1-10 μM. |
1402837-77-7 |
DC46155 |
BMT-297376
BMT-297376, the optimized Linrodostat, is a potent IDO1 inhibitor. |
2251031-81-7 |
DC47596 |
IDO-IN-15
IDO-IN-15 is an IDO1 inhibitor (IC50 < 0.51 nM). |
2433886-87-2 |
DC47597 |
IDO-IN-14
IDO-IN-14 is an IDO inhibitor with an IC50 value of 0.6928 nM. |
2568302-02-1 |
DC48216 |
NLG802
NLG802 is a prodrug of indoximod, an orally active indoleamine 2,3-dioxygenase (IDO) inhibitor. |
2071683-99-1 |
DC48217 |
IDO1-IN-11
IDO1-IN-11 is an IDO1 inhibitor with an IC50 value of 0.6 nM. |
2306411-34-5 |
DC48218 |
IDO1-IN-12
IDO1-IN-12 is a potent and orally available IDO1 inhibitor. |
2379570-48-4 |
DC48664 |
IDO1/2-IN-1
IDO1/2-IN-1 (compound 4t) is the first potent IDO1/IDO2 dual inhibitor with IC50s of 28 nM and 144 nM for IDO1 and IDO2, respectively. IDO1/2-IN-1 exhibits antitumor activies. Orally active. |
2310286-45-2 |
DC49739 |
IDO1-IN-13
IDO1-IN-13 (compound 27a) is a potent IDO1 inhibitor with an IC50 of 61.6 nM. IDO1-IN-13 has cellular IDO1 inhibition (HeLa EC50= 30 nM). IDO1-IN-13 decreases 51% of the kyn/trp ratio in SK-OV-3 xenograft tumor tissues. |